294848-51-4

Upstream product

• 294851-99-3 1-amino-4-[6-(morpholin-4-ylmethyl)pyridin-3-yl]naphthalene 
• 285984-47-6 [5-tert-butyl-2-(4-methylphenyl)-2H-pyrazol-3-yl]carbamic acid phenyl ester 
• 317806-87-4 2,2,2-trichloroethyl 3-tert-butyl-1-p-tolyl-1H-pyrazol-5-ylcarbamate 
• 2298-07-9 4-Bromo-1-naphthylamine 
• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 294851-95-9 4-[(5-bromo-2-pyridinyl)-methyl]morpholine 

Downstream Products

• 950666-03-2 1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]urea besylate 

Relevant academic research and scientific papers

New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site

Discovery of the pyrazole-naphthyl urea class of p38 MAP kinase inhibitors typified by the clinical candidate BIRB 796 has encouraged further exploration of this particular scaffold. Modification to the part of the inhibitor that occupies the adenine/ATP

Polymorph and process for preparing same

Disclosed are processes, polymorph and intermediate compounds for preparing aryl- and heteroaryl-substituted urea compounds of the formula(I) wherein Ar1, Ar2, L, Q and X are described herein. The product compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. 1

Method of treating mucus hypersecretion

The invention relates to the use of p38 kinase inhibitors for the preparation of a pharmaceutical composition suitable for inhalation for the treatment of mucus hypersecretion. Furthermore the invention is directed to pharmaceutical compositions suitable for inhalation comprising p38 kinase inhibitors and to methods for the preparation thereof.

Methods of treating cytokine mediated diseases

Disclosed are methods of treating acute and chronic inflammation in the lung caused by inhalation of smoke, endometriosis, Behcet's disease, uveitis, ankylosing spondylitis, pancreatitis, cancer, Lyme disease, sepsis, chronic obstructive pulmonary disease, traumatic arthritis, congestive heart failure and restenosis following percutaneous transluminal coronary angioplasty, known to be cytokine mediated, using aromatic heterocyclic compounds described in WO 00/55139.